Hunan Jingfeng Pharmaceutical (000908) — Strategic Asset Allocation Index
Hunan Jingfeng Pharmaceutical (000908) has a Strategic Asset Allocation Index of 278.6% as of September 2023. Strategic assets (PP&E of CN¥522.82 Million plus long-term investments of CN¥-) total CN¥522.82 Million, measured against net assets of CN¥187.65 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. For live market cap and overall valuation, see Hunan Jingfeng Pharmaceutical market capitalisation.
SAAI
Strategic Assets
PP&E
Net Assets
Hunan Jingfeng Pharmaceutical Strategic Asset Allocation Index (2000–2022)
This chart shows how Hunan Jingfeng Pharmaceutical's Strategic Asset Allocation Index has evolved across 22 annual periods from 2000 to 2022. As of September 2023, the index stands at 278.6%, representing strategic assets of CN¥522.82 Million against net assets of CN¥187.65 Million CNY. See Hunan Jingfeng Pharmaceutical balance sheet quality to measure how much of total assets are equity-financed.
Annual Strategic Asset Allocation Index for Hunan Jingfeng Pharmaceutical (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Hunan Jingfeng Pharmaceutical from 2000 to 2022, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. Also explore how fast is Hunan Jingfeng Pharmaceutical growing its equity to track the company's year-over-year net asset growth rate.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 263.7% | CN¥566.42 Million | CN¥566.42 Million | CN¥- | CN¥214.83 Million | ▲ +42.1 pp |
| 2021 | 221.6% | CN¥726.10 Million | CN¥726.10 Million | CN¥- | CN¥327.73 Million | ▲ +62.7 pp |
| 2020 | 158.9% | CN¥1.01 Billion | CN¥1.01 Billion | CN¥- | CN¥638.18 Million | ▲ +95.4 pp |
| 2019 | 63.4% | CN¥1.23 Billion | CN¥1.23 Billion | CN¥- | CN¥1.94 Billion | ▲ +14.8 pp |
| 2018 | 48.7% | CN¥1.39 Billion | CN¥1.05 Billion | CN¥343.64 Million | CN¥2.86 Billion | ▲ +5.4 pp |
| 2017 | 43.3% | CN¥1.13 Billion | CN¥784.97 Million | CN¥340.28 Million | CN¥2.60 Billion | ▲ +9.3 pp |
| 2016 | 34.0% | CN¥888.29 Million | CN¥667.68 Million | CN¥220.60 Million | CN¥2.61 Billion | ▲ +2.0 pp |
| 2015 | 32.0% | CN¥719.73 Million | CN¥483.86 Million | CN¥235.86 Million | CN¥2.25 Billion | ▼ -2.9 pp |
| 2014 | 34.9% | CN¥347.39 Million | CN¥347.39 Million | CN¥- | CN¥994.04 Million | ▼ -2278.4 pp |
| 2013 | 2313.4% | CN¥122.81 Million | CN¥122.81 Million | CN¥- | CN¥5.31 Million | ▼ -18493.5 pp |
| 2011 | 20806.9% | CN¥164.54 Million | CN¥164.54 Million | CN¥- | CN¥790.82K | ▲ +20552.8 pp |
| 2010 | 254.1% | CN¥147.00 Million | CN¥147.00 Million | CN¥- | CN¥57.85 Million | ▲ +95.4 pp |
| 2009 | 158.8% | CN¥159.84 Million | CN¥159.84 Million | CN¥- | CN¥100.67 Million | ▲ +100.9 pp |
| 2008 | 57.9% | CN¥196.07 Million | CN¥196.07 Million | CN¥- | CN¥338.64 Million | ▼ -1.0 pp |
| 2007 | 58.9% | CN¥198.35 Million | CN¥198.35 Million | CN¥- | CN¥336.95 Million | ▼ -24.1 pp |
| 2006 | 83.0% | CN¥279.25 Million | CN¥279.25 Million | CN¥- | CN¥336.40 Million | ▼ -0.3 pp |
| 2005 | 83.3% | CN¥274.63 Million | CN¥274.63 Million | CN¥- | CN¥329.66 Million | ▲ +40.2 pp |
| 2004 | 43.1% | CN¥146.33 Million | CN¥146.33 Million | CN¥- | CN¥339.45 Million | ▲ +0.4 pp |
| 2003 | 42.7% | CN¥179.07 Million | CN¥179.07 Million | CN¥- | CN¥419.38 Million | ▲ +6.5 pp |
| 2002 | 36.2% | CN¥189.15 Million | CN¥189.15 Million | CN¥- | CN¥522.69 Million | ▲ +4.4 pp |
| 2001 | 31.8% | CN¥158.37 Million | CN¥158.37 Million | CN¥- | CN¥498.41 Million | ▲ +8.8 pp |
| 2000 | 23.0% | CN¥115.11 Million | CN¥115.11 Million | CN¥- | CN¥500.54 Million | — |